IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis

BACKGROUND: Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of this st...

Descripción completa

Detalles Bibliográficos

Autores principales:	Vergis, N., Patel, V., Bogdanowicz, K., Czyzewska-Khan, J., Fiorentino, F., Day, E., Cross, M., Foster, N., Lord, E., Goldin, R., Forrest, E., Thursz, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581959/ https://www.ncbi.nlm.nih.gov/pubmed/34763711 http://dx.doi.org/10.1186/s13063-021-05719-2